On July 28, 2026, CeriBell, Inc.'s Board rebalanced its director classes by re-electing William W. Burke to Class II and Joseph M. Taylor to Class III. The Board increased its authorized size from seven to nine directors and elected Sharon L. O’Keefe and Thomas A. West as new Class I directors. Each new director received an initial restricted stock unit award valued at $300,000 based on the average closing price over the prior 30 trading days. CeriBell develops medical devices for continuous electroencephalography monitoring.